Addressing dyslipidemia is crucial to reducing the burden imposed by cardiovascular disease. However, many current statins have major limitations. Moreover, innovative treatments need to address ...
Clin Lipidology. 2010;5(3):309-323. Transporter molecules also contribute to statins' pharmacokinetic profile. For example, p-glycoprotein shares several substrates with CYP3A4, including several ...
Aug. 14, 2024 — More than a quarter of Australians over the age of 50 take cholesterol-lowering drugs to prevent heart disease and strokes, but our bodies also need cholesterol to survive.